Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 24, Issue 29, 2006, Pages 4721-4730

  Nemunaitis, John ^a   Dillman, Robert O ^a   Schwarzenberger, Paul O ^a   Senzer, Neil ^a   Cunningham, Casey ^a   Cutler, Jodi ^a   Tong, Alex ^a   Kumar, Padmasini ^a   Pappen, Beena ^a   Hamilton, Cody ^a   DeVol, Edward ^a   Maples, Phillip B ^a   Liu, Lily ^a   Chamberlin, Terry ^a   Shawler, Daniel L ^a   Fakhrai, Habib ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELAGENPUMATUCEL L; DNA FRAGMENT; ERLOTINIB; GAMMA INTERFERON; GEFITINIB; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; TGFB2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTISENSE VECTOR; ARTICLE; BREATHING DISORDER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DIARRHEA; DOSE RESPONSE; DYSPHAGIA; EDEMA; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGUS DISEASE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN BRUISING; SORE THROAT; TREATMENT OUTCOME; VACCINATION; VOMITING; WEAKNESS; WEIGHT REDUCTION; ANTIBODY PRODUCTION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TREATMENT OUTCOME;

EID: 33750586798     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.5335     Document Type: Article

References (86)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 37.S4-S66, 2001 (suppl 8)
2. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-890, 1995
4. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
7. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
8. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
9. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
11. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290:2149-2158, 2003
12. Nemunaitis J: Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 4:259-274, 2005
13. Nemunaitis J, Sterman D, Jablons D, et al: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96:326-331, 2004
14. Fakhrai H, Gramatikova S, Safaei R: Down-regulation of TGF-b2 as a therapeutic approach, in Brain Tumor Immunotherapy. Totowa, NJ, Humana Press, 2001, pp 289-305
15. Sporn MB, Roberts AB, Wakefield LM, et al: Transforming growth factor-beta: Biological function and chemical structure. Science 233:532-534, 1986
16. Massague J: The TGF-beta family of growth and differentiation factors. Cell 49:437-438, 1987
17. Border WA, Ruoslahti E: Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 90:1-7, 1992
18. Bodmer S, Strommer K, Frei K, et al: Immunosuppression and transforming growth factor-beta in glioblastoma: Preferential production of transforming growth factor-beta 2. J Immunol 143:3222-3229, 1989
19. Jakowlew SB, Mathias A, Chung P, et al: Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 6:465-476, 1995
20. Constam DB, Philipp J, Malipiero UV, et al: Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404-1410, 1992
21. Kong F, Jirtle RL, Huang DH, et al: Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86:1712-1719, 1999
22. Rook AH, Kehrl JH, Wakefield LM, et al: Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916-3920, 1986
23. Kasid A, Bell GI, Director EP: Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors: Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141:690-698, 1988
24. Tsunawaki S, Sporn M, Ding A, et al: Deactivation of macrophages by transforming growth factor-beta. Nature 334:260-262, 1988
25. Hirte H, Clark DA: Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 32:296-302, 1991
26. Naganuma H, Sasaki A, Satoh E, et al: Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) 36:789-795, 1996
27. Ruffini PA, Rivoltini L, Silvani A, et al: Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36:409-416, 1993
28. Fakhrai H, Mantil JC, Liu L, et al: Phase I clinical trial of TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Therapy (in press)
29. Liau LM, Fakhrai H, Black KL: Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 20:742-747, 1998
30. Dorigo O, Shawler DL, Royston I, et al: Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol 71:204-210, 1998
31. Tzai TS, Shiau AL, Liu LL, et al: Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res 20:1557-1562, 2000
32. Tzai TS, Lin CI, Shiau AL, et al: Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res 18:1585-1589, 1998
33. Marzo AL, Fitzpatrick DR, Robinson BW, et al: Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57:3200-3207, 1997
34. Park JA, Wang E, Kurt RA, et al: Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther 4:42-50, 1997
35. Kettering JD, Mohamedali AM, Green LM, et al: IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression. Technol Cancer Res Treat 2:211-221, 2003
36. Fakhrai H, Dorigo O, Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2909-2914, 1996
37. Salgaller ML: The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2:265-278, 2002
38. Ratto GB, Zino P, Mirabelli S, et al: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78:244-251, 1996
39. Lissoni P, Meregalli S, Fossati V, et al: A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 80:464-467, 1994
40. Ratto GB, Cafferata MA, Scolaro T, et al: Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 23:161-167, 2000
41. Salgia R, Lynch T, Skarin A, et al: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21:624-630, 2003
42. Soiffer R, Hodi FS, Haluska F, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21:3343-3350, 2003
43. Morse MA: Technology evaluation: BLP-25, Biomira Inc. Curr Opin Mol Ther 3:102-105, 2001
44. Woo EY, Chu CS, Goletz TJ, et al: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766-4772, 2001
45. Woo EY, Yeh H, Chu CS, et al: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276, 2002
46. Sienel W, Varwerk C, Linder A, et al: Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: Results of a multi-center study. Eur J Cardiothorac Surg 25:131-134, 2004
47. Yamazaki K, Spruill G, Rhoderick J, et al: Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Cancer Res 59:4642-4650, 1999
48. Weynants P, Thonnard J, Marchand M, et al: Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med 159:55-62, 1999
49. Bixby DL, Yannelli JR: CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 78:685-694, 1998
50. Yamada A, Kawano K, Koga M, et al: Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res 63:2829-2835, 2003
51. Jiang F, Yin Z, Caraway NP, et al: Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia 6:623-635, 2004
52. Melloni G, Ferreri AJ, Russo V, et al: Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 12:145-151, 2004
53. Neuner A, Schindel M, Wildenberg U, et al: Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 101:287-292, 2002
54. Neuner A, Schindel M, Wildenberg U, et al: Cytokine secretion: Clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer 34:S79-S82, 2001 (suppl 2)
55. Dohadwala M, Luo J, Zhu L, et al: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276:20809-20812, 2001
56. Schwartz RH: Models of T cell anergy: Is there a common molecular mechanism? J Exp Med 184:1-8, 1996
57. Lombardi G, Sidhu S, Batchelor R, et al: Anergic T cells as suppressor cells in vitro. Science 264:1587-1589, 1994
58. Chen W, Jin W, Hardegen N, et al: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875-1886, 2003
59. Fantini MC, Becker C, Monteleone G, et al: Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172:5149-5153, 2004
60. Groh V, Rhinehart R, Secrist H, et al: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96:6879-6884, 1999
61. Bauer S, Groh V, Wu J, et al: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729, 1999
62. Friese MA, Wischhusen J, Wick W, et al: RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596-7603, 2004
63. Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194:629-644, 2001
64. Annunziato F, Cosmi L, Liotta F, et al: Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 196:379-387, 2002
65. Parekh W, Prasad DV, Banerjee PP, et al: B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: Role of TGF-beta 1. J Immunol 170:5897-5911, 2003
66. Castelli C, Rivoltini L, Andreola G, et al: T-cell recognition of melanoma-associated antigens. J Cell Physiol 182:323-331, 2000
67. Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370-374, 1991
68. Smith KA: Interleukin-2: Inception, impact, and implications. Science 240:1169-1176, 1988
69. Smith KA: Lowest dose interleukin-2 immunotherapy. Blood 81:1414-1423, 1993
70. Tigges MA, Casey LS, Koshland ME: Mechanism of interleukin-2 signaling: Mediation of different outcomes by a single receptor and transduction pathway. Science 243:781-786, 1989
71. Fontana A, Frei K, Bodmer S, et al: Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 143:3230-3234, 1989
72. Hirte HW, Clark DA, O'Connell G, et al: Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol 142:207-216, 1992
73. Ranges GE, Figari IS, Espevik T, et al: Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166:991-998, 1987
74. Ahmadzadeh M, Rosenberg SA: TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174:5215-5223, 2005
75. Gorelik L, Constant S, Flavell RA: Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 195:1499-1505, 2002
76. Maggard M, Meng L, Ke B, et al: Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: Treatment in a rat tumor model. Ann Surg Oncol 8:32-37, 2001
77. Hirschowitz EA, Foody T, Kryscio R, et al: Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22:2808-2815, 2004
78. Raez LE, Cassileth PA, Schlesselman JJ, et al: Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:2800-2807, 2004
79. Fong L, Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273, 2000
80. Boon T, Cerottini JC, Van den Eynde B, et al: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365, 1994
81. Nestle FO, Burg G, Fah J, et al: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 150:641-651, 1997
82. Enk AH, Jonuleit H, Saloga J, et al: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316, 1997
83. Yamaguchi Y, Tsumura H, Miwa M, et al: Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15:144-153, 1997
84. Sato K, Kawasaki H, Nagayama H, et al: TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol 164:2285-2295, 2000
85. Weber F, Byrne SN, Le S, et al: Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunol Immunother 54:898-906, 2005
86. Overwijk WW: Breaking tolerance in cancer immunotherapy: Time to ACT. Curr Opin Immunol 17:187-194, 2005